Levodopa

Handbook of Clinical Neurology

Volumn 84, Issue , 2007, Pages 31-72

  Hälbig, Thomas D ^a   Koller, William C ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67649347925     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0072-9752(07)84032-2     Document Type: Chapter

References (438)

1. Aarsland D., and Karlsen K. Neuropsychiatric aspects of Parkinson's disease. Curr Psychiatry Rep 1 (1999) 61-68
2. Abate G., Polimeni R.M., Cuccurullo F., et al. Effects of indomethacin on postural hypotension in Parkinsonism. Br Med J 2 (1979) 1466-1468
3. Acquas E., Carboni E., de Ree R.H., et al. Extracellular concentrations of dopamine and metabolites in the rat caudate after oral administration of a novel catechol-O-methyltransferase inhibitor Ro 40-7592. J Neurochem 59 (1992) 326-330
4. Adler C.H., Singer C., O'Brien C., et al. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III. Arch Neurol 55 (1998) 1089-1095
5. Agid Y., Bonnet A.M., Ruberg M., et al. Pathophysiology of L-dopa-induced abnormal involuntary movements. Psychopharmacology Suppl 2 (1985) 145-159
6. Agid Y., Javoy-Agid F., and Ruberg M. Biochemistry of neurotransmitters in Parkinson's disease. In: Marsden C.D., and Fahn S. (Eds). Movement Disorders 2 (1987), Butterworths, London 166-230
7. Ahlskog J.E., and Muenter M.D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16 (2001) 448-458
8. Ahlskog J.E., Muenter M.D., McManis P.G., et al. Controlled-release Sinemet (CR-4): a double-blind crossover study in patients with fluctuating Parkinson's disease. Mayo Clin Proc 63 (1988) 876-886
9. Ahlskog J.E., Uitti R.J., O'Connor M.K., et al. The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease. Mov Disord 14 (1999) 940-946
10. Ahtila S., Kaakkola S., Gordin A., et al. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers. Clin Neuropharmacol 18 (1995) 46-57
11. Allain P., Le Bouil A., Cordillet E., et al. Sulfate and cysteine levels in the plasma of patients with Parkinson's disease. Neurotoxicology 16 (1995) 527-529
12. APA. Diagnostic and Statistical Manual of Mental Disorders, DSM-IV-TR. Fourth Edn. (2000), American Psychiatric Association, Washington DC
13. Arnulf I., Bonnet A.M., Damier P., et al. Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis. Neurology 55 (2000) 281-288
14. Assal F., Spahr L., Hadengue A., et al. Tolcapone and fulminant hepatitis. Lancet 352 (1998) 958
15. Avanzi M., Uber E., and Bonfa F. Pathological gambling in two patients on dopamine replacement therapy for Parkinson's disease. Neurol Sci 25 (2004) 98-101
16. Baas H., Beiske A.G., Ghika J., et al. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry 63 (1997) 421-428
17. Barbeau A., Sourkes T., and Murphy G. Les Catecholamines dans la Maladie de Parkinson (1962), Georg, Geneva
18. Barnes J., and David A.S. Visual hallucinations in Parkinson's disease: a review and phenomenological survey. J Neurol Neurosurg Psychiatry 70 (2001) 727-733
19. Barone J.A. Domperidone: a peripherally acting dopamine2-receptor antagonist. Ann Pharmacother 33 (1999) 429-440
20. Bartholini G., Burkard W.P., and Pletscher A. Increase of cerebral catecholamines caused by 3,4-dihydroxyphenylalanine after inhibition of peripheral decarboxylase. Nature 215 (1967) 852-853
21. Bayer A.J., Day J.J., Finucane P., et al. Bioavailability and acceptability of a dispersible formulation of levodopa-benserazide in parkinsonian patients with and without dysphagia. J Clin Pharm Ther 13 (1988) 191-194
22. Bedard P.J., Di Paolo T., Falardeau P., et al. Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding. Brain Res 379 (1986) 294-299
23. Ben-Shlomo Y., and Marmot M.G. Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology?. J Neurol Neurosurg Psychiatry 58 (1995) 293-299
24. Berger C., Mehrhoff F.W., Beier K.M., et al. [Sexual delinquency and Parkinson's disease.]. Nervenarzt 74 (2003) 370-375
25. Birkmayer W. The importance of monoamine metabolism for the pathology of the extrapyramidal system. J Neurovisc Relat 31 Suppl 9 (1969) 297
26. Birkmayer W., and Hornykiewicz O. [The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia.]. Wien Klin Wochenschr 73 (1961) 787-788
27. Blanchet P.J., Calon F., Martel J.C., et al. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys. J Pharmacol Exp Ther 272 (1995) 854-859
28. Block G., Liss C., Reines S., et al. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group. Eur Neurol 37 (1997) 23-27
29. Borges N., Vieira-Coelho M.A., Parada A., et al. Studies on the tight-binding nature of tolcapone inhibition of soluble and membrane-bound rat brain catechol-O-methyltransferase. J Pharmacol Exp Ther 282 (1997) 812-817
30. Bostom A.G., Rosenberg I.H., Silbershatz H., et al. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham Study. Ann Intern Med 131 (1999) 352-355
31. Bostom A.G., Silbershatz H., Rosenberg I.H., et al. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch Intern Med 159 (1999) 1077-1080
32. Bouhaddi M., Vuillier F., Fortrat J.O., et al. Impaired cardiovascular autonomic control in newly and long-term-treated patients with Parkinson's disease: involvement of L-dopa therapy. Auton Neurosci 116 (2004) 30-38
33. Bradbrook I.D., Gillies H.C., Morrison P.J., et al. The effects of domperidone on the absorption of levodopa in normal subjects. Eur J Clin Pharmacol 29 (1986) 721-723
34. Brandstadter D., and Oertel W.H. Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson's disease. Neurology 58 (2002) 160-161
35. Bravi D., Mouradian M.M., Roberts J.W., et al. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms. Ann Neurol 36 (1994) 27-31
36. Breier A., Sutton V.K., Feldman P.D., et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biol Psychiatry 52 (2002) 438-445
37. Brevetti G., Bonaduce D., Breglio R., et al. Parkinson's disease and hypotension: 24-hour blood pressure recording in ambulant patients. Clin Cardiol 13 (1990) 474-478
38. Brooks D.J. Safety and tolerability of COMT inhibitors. Neurology 62 (2004) S39-S46
39. Brooks D.J., Sagar H., and UK-Irish Entacapone Study Group. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry 74 (2003) 1071-1079
40. Burguera J.A., Grandas F., Horga de la Parte J.F., et al. [Entacapone: is it useful as complimentary treatment with levodopa?]. Rev Neurol 28 (1999) 817-834
41. Byrne K.G., Pfeiffer R., and Quigley E.M. Gastrointestinal dysfunction in Parkinson's disease. A report of clinical experience at a single center. J Clin Gastroenterol 19 (1994) 11-16
42. Calne D.B. L-Dopa in the treatment of parkinsonism. Clin Pharmacol Ther 11 (1970) 789-801
43. Calne D.B., Brennan J., Spiers A.S., et al. Hypotension caused by L-dopa. Br Med J 1 (1970) 474-475
44. Calne D.B., Reid J.L., Vakil S.D., et al. Idiopathic Parkinsonism treated with an extracerebral decarboxylase inhibitor in combination with levodopa. Br Med J 3 (1971) 729-732
45. Calon F., Goulet M., Blanchet P.J., et al. Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA receptors in the striatopallidal complex. Brain Res 680 (1995) 43-52
46. Calon F., Grondin R., Morissette M., et al. Molecular basis of levodopa-induced dyskinesias. Ann Neurol 47 (2000) S70-S78
47. Camerlingo M., Ferraro B., Gazzaniga G.C., et al. Cardiovascular reflexes in Parkinson's disease: long-term effects of levodopa treatment on de novo patients. Acta Neurol Scand 81 (1990) 346-348
48. Cedarbaum J.M., Kutt H., Dhar A.K., et al. Effect of supplemental carbidopa on bioavailability of L-dopa. Clin Neuropharmacol 9 (1986) 153-159
49. Cedarbaum J.M., Breck L., Kutt H., et al. Controlled-release levodopa/carbidopa. II. Sinemet CR4 treatment of response fluctuations in Parkinson's disease. Neurology 37 (1987) 1607-1612
50. Cedarbaum J.M., Silvestri M., and Kutt H. Sustained enteral administration of levodopa increases and interrupted infusion decreases levodopa dose requirements. Neurology 40 (1990) 995-997
51. Cedarbaum J.M., Silvestri M., Clark M., et al. Results of long-term treatment with controlled-release levodopa/ carbidopa (Sinemet CR). J Neural Transm Park Dis Dement Sect 2 (1990) 205-213
52. 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease. Synapse 43 (2002) 201-207
53. Chapuis S., Ouchchane L., Metz O., et al. Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord 20 (2004) 224-230
54. Chouza C., Aljanati R., Caamano J.L., et al. Long-term treatment with Madopar HBS in parkinsonians with fluctuations. Adv Neurol 53 (1990) 519-526
55. Clarke C.E., Sambrook M.A., Mitchell I.J., et al. Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP). J Neurol Sci 78 (1987) 273-280
56. Comella C.L., and Goetz C.G. Akathisia in Parkinson's disease. Mov Disord 9 (1994) 545-549
57. Contin M., Riva R., Martinelli P., et al. Concentration-effect relationship of levodopa-benserazide dispersible formulation versus standard form in the treatment of complicated motor response fluctuations in Parkinson's disease. Clin Neuropharmacol 22 (1999) 351-355
58. Cook J.W., Taylor L.M., Orloff S.L., et al. Homocysteine and arterial disease. Experimental mechanisms. Vascul Pharmacol 38 (2002) 293-300
59. Corona-Morales A.A., Castell A., and Zhang L. L-DOPA-induced neurotoxic and apoptotic changes on cultured chromaffin cells. Neuroreport 11 (2000) 503-506
60. Cotzias G.C., Van Woert M.H., and Schiffer L.M. Aromatic amino acids and modification of parkinsonism. N Engl J Med 276 (1967) 374-379
61. Cotzias G.C., Papavasiliou P.S., and Gellene R. Modification of Parkinsonism-chronic treatment with L-dopa. N Engl J Med 280 (1969) 337-345
62. Crevoisier C., Hoevels B., Zurcher G., et al. Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. Eur Neurol 27 Suppl 1 (1987) 36-46
63. Da Prada M., Kettler R., Zurcher G., et al. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers. Eur Neurol 27 Suppl 1 (1987) 9-20
64. Datla K.P., Blunt S.B., and Dexter D.T. Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions. Mov Disord 16 (2001) 424-434
65. de la Fuente-Fernandez R., Nunez M.A., and Lopez E. The apolipoprotein E epsilon 4 allele increases the risk of drug-induced hallucinations in Parkinson' disease. Clin Neuropharmacol 22 (1999) 226-230
66. de Maindreville A.D., Fenelon G., and Mahieux F. Hallucinations in Parkinson's disease: a follow-up study. Mov Disord 20 (2005) 212-217
67. De Michele G., Mengano A., Filla A., et al. A double-blind, cross-over trial with madopar HBS in patients with Parkinson's disease. Acta Neurol (Napoli) 11 (1989) 408-414
68. de Smet Y., Ruberg M., Serdaru M., et al. Confusion, dementia and anticholinergics in Parkinson's disease. J Neurol Neurosurg Psychiatry 45 (1982) 1161-1164
69. Deleu D., Jacques M., Michotte Y., et al. Clinical and pharmacokinetic evaluation of controlled-release levodopa/carbidopa (CR-4) in parkinsonian patients with severe motor fluctuations: a six month follow-up study. Clin Neurol Neurosurg 91 (1989) 303-309
70. DeLong M.R., Crutcher M.D., and Georgopoulos A.P. Relations between movement and single cell discharge in the substantia nigra of the behaving monkey. J Neurosci 3 (1983) 1599-1606
71. den Heijer T., Vermeer S.E., Clarke R., et al. Homocysteine and brain atrophy on MRI of non-demented elderly. Brain 126 (2003) 170-175
72. Descombes S., Bonnet A.M., Gasser U.E., et al. Dual-release formulation, a novel principle in L-dopa treatment of Parkinson's disease. Neurology 56 (2001) 1239-1242
73. Dewey Jr. R.B., and O'Suilleabhain P.E. Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson's disease. Neurology 55 (2000) 1753-1754
74. Dexter D.T., Wells F.R., Agid F., et al. Increased nigral iron content in postmortem parkinsonian brain. Lancet 2 (1987) 1219-1220
75. Dexter D.T., Wells F.R., Lees A.J., et al. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 52 (1989) 1830-1836
76. Dingemanse J., Jorga K., Zurcher G., et al. Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br J Clin Pharmacol 40 (1995) 253-262
77. Dingemanse J., Jorga K.M., Schmitt M., et al. Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans. Clin Pharmacol Ther 57 (1995) 508-517
78. Dingemanse J., Jorga K., Zurcher G., et al. Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects. Eur J Clin Pharmacol 50 (1996) 47-55
79. Djaldetti R., Baron J., Ziv I., et al. Gastric emptying in Parkinson's disease: patients with and without response fluctuations. Neurology 46 (1996) 1051-1054
80. Djaldetti R., Inzelberg R., Giladi N., et al. Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease. Mov Disord 17 (2002) 297-302
81. Djaldetti R., Giladi N., Hassin-Baer S., et al. Pharmacokinetics of etilevodopa compared to levodopa in patients with Parkinson's disease: an open-label, randomized, crossover study. Clin Neuropharmacol 26 (2003) 322-326
82. Dodd M.L., Klos K.J., Bower J.H., et al. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 62 (2005) 1377-1381
83. Driver-Dunckley E., Samanta J., and Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology 61 (2003) 422-423
84. Duan W., Ladenheim B., Cutler R.G., et al. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J Neurochem 80 (2002) 101-110
85. Dufouil C., Alperovitch A., Ducros V., et al. Homocysteine, white matter hyperintensities, and cognition in healthy elderly people. Ann Neurol 53 (2003) 214-221
86. Dupont E., Andersen A., Boas J., et al. Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients. Acta Neurol Scand 93 (1996) 14-20
87. Duty S., and Brotchie J.M. Enhancement of the behavioral response to apomorphine administration following repeated treatment in the 6-hydroxydopamine-lesioned rat is temporally correlated with a rise in striatal preproenkephalin-B, but not preproenkephalin-A, gene expression. Exp Neurol 144 (1997) 423-432
88. Duvoisin R.C. Diphenidol for levodopa induced nausea and vomiting. JAMA 221 (1972) 1408
89. Edwards L.L., Quigley E.M., and Pfeiffer R.F. Gastrointestinal dysfunction in Parkinson's disease: frequency and pathophysiology. Neurology 42 (1992) 726-732
90. Ehringer H., and Hornykiewicz O. [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system]. Klin Wochenschr 38 (1960) 1236-1239
91. Eisler T., Eng N., Plotkin C., et al. Absorption of levodopa after rectal administration. Neurology 31 (1981) 215-217
92. Emerit J., Edeas M., and Bricaire F. Neurodegenerative diseases and oxidative stress. Biomed Pharmacother 58 (2004) 39-46
93. Emre M. Dementia associated with Parkinson's disease. Lancet Neurol 2 (2003) 229-237
94. Erni W., and Held K. The hydrodynamically balanced system: a novel principle of controlled drug release. Eur Neurol 27 Suppl 1 (1987) 21-27
95. Evans A.H., Katzenschlager R., Paviour D., et al. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord 19 (2004) 397-405
96. Fabbrini G., Mouradian M.M., Juncos J.L., et al. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I. Ann Neurol 24 (1988) 366-371
97. Factor S.A., Molho E.S., Feustel P.J., et al. Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease. Clin Neuropharmacol 24 (2001) 295-299
98. Fahn S. "On-off" phenomenon with levodopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine. Neurology 24 (1974) 431-441
99. Fahn S., and Elton R. Members of the UPDRS Development Committee. In: Fahn S., Marsden C.D., Calne D.B., and Goldstein M. (Eds). Recent Developments in Parkinson's Disease Vol. 2. (1987), Macmillan Health Care Information, Florham Park, NJ 153-163 293-304
100. Fehling C. Treatment of Parkinson's syndrome with L-dopa. A double blind study. Acta Neurol Scand 42 (1966) 367-372
101. Feldman R.G., Mosbach P.A., Kelly M.R., et al. Double-blind comparison of standard Sinemet and Sinemet CR in patients with mild-to-moderate Parkinson's disease. Neurology 39 (1989) 96-101 discussion 105
102. Fenelon G., Mahieux F., Huon R., et al. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 123 Pt 4 (2000) 733-745
103. Fernandez H.H., and Friedman J.H. Punding on L-dopa. Mov Disord 14 (1999) 836-838
104. Fernandez H.H., Friedman J.H., Jacques C., et al. Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 14 (1999) 484-487
105. Fernandez H.H., Trieschmann M.E., and Friedman J.H. Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience. Clin Neuropharmacol 27 (2004) 4-5
106. Fiala K.H., Whetteckey J., and Manyam B.V. Malignant melanoma and levodopa in Parkinson's disease: causality or coincidence?. Parkinsonism Relat Disord 9 (2003) 321-327
107. Fiorillo C.D., Tobler P.N., and Schultz W. Discrete coding of reward probability and uncertainty by dopamine neurons. Science 299 (2003) 1898-1902
108. Fisher A., Croft-Baker J., Davis M., et al. Entacapone-induced hepatotoxicity and hepatic dysfunction. Mov Disord 17 (2002) 1362-1365 discussion 1397-1400
109. French Clozapine Parkinson Study Group. Clozapine in drug-induced psychosis in Parkinson's disease. The French Clozapine Parkinson Study Group. Lancet 353 (1999) 2041-2042
110. Friedman J.H. The management of the levodopa psychoses. Clin Neuropharmacol 14 (1991) 283-295
111. Friedman J.H., and Lannon M.C. Clozapine in the treatment of psychosis in Parkinson's disease. Neurology 39 (1989) 1219-1221
112. Friedman J.H., and Lannon M.C. An open trial of controlled release carbidopa/L-dopa (sinemet CR) for the treatment of mild-to-moderate Parkinson's disease. Clin Neuropharmacol 12 (1989) 220-223
113. Gancher S.T., Nutt J.G., and Woodward W. Response to brief levodopa infusions in parkinsonian patients with and without motor fluctuations. Neurology 38 (1988) 712-716
114. Garcia Ruiz P.J., Meseguer E., Del Val J., et al. Motor complications in Parkinson disease: a prospective follow-up study. Clin Neuropharmacol 27 (2004) 49-52
115. Genedani S., Rasio G., Cortelli P., et al. Studies on homocysteine and dehydroepiandrosterone sulphate plasma levels in Alzheimer's disease patients and in Parkinson's disease patients. Neurotox Res 6 (2004) 327-332
116. Gerfen C.R., Engber T.M., Mahan L.C., et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250 (1990) 1429-1432
117. Giovannoni G., O'Sullivan J.D., Turner K., et al. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 68 (2000) 423-428
118. Giros B., and Caron M.G. Molecular characterization of the dopamine transporter. Trends Pharmacol Sci 14 (1993) 43-49
119. Goetz C.G., and Stebbins G.T. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 43 (1993) 2227-2229
120. Goetz C.G., Tanner C.M., Shannon K.M., et al. Controlled-release carbidopa/levodopa (CR4-Sinemet) in Parkinson's disease patients with and without motor fluctuations. Neurology 38 (1988) 1143-1146
121. Goetz C.G., Tanner C.M., Gilley D.W., et al. Development and progression of motor fluctuations and side effects in Parkinson's disease: comparison of Sinemet CR versus carbidopa/levodopa. Neurology 39 (1989) 63-66 discussion 72-63
122. Goetz C.G., Pappert E.J., Blasucci L.M., et al. Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations. Neurology 50 (1998) 515-517
123. Goetze O., Wieczorek J., Mueller T., et al. Impaired gastric emptying of a solid test meal in patients with Parkinson's disease using (13)C-sodium octanoate breath test. Neurosci Lett 375 (2005) 170-173
124. Golbe L.I. Young-onset Parkinson's disease: a clinical review. Neurology 41 (1991) 168-173
125. Goldberg L.I., and Rajfer S.I. Dopamine receptors: applications in clinical cardiology. Circulation 72 (1985) 245-248
126. Goldstein D.S., Holmes C.S., Dendi R., et al. Orthostatic hypotension from sympathetic denervation in Parkinson's disease. Neurology 58 (2002) 1247-1255
127. Gordin A., Kaakkola S., and Teravainen H. Position of COMT inhibition in the treatment of Parkinson's disease. Adv Neurol 91 (2003) 237-250
128. Gorell J.M., Johnson C.C., and Rybicki B.A. Parkinson's disease and its comorbid disorders: an analysis of Michigan mortality data, 1970 to 1990. Neurology 44 (1994) 1865-1868
129. Grace A.A. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41 (1991) 1-24
130. Graham D.G., Tiffany S.M., Bell Jr. W.R., et al. Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol Pharmacol 14 (1978) 644-653
131. Grahnen A., Eckernas S.A., Collin C., et al. Comparative multiple-dose pharmacokinetics of controlled-release levodopa products. Eur Neurol 32 (1992) 343-348
132. Grandas F., Galiano M.L., and Tabernero C. Risk factors for levodopa-induced dyskinesias in Parkinson's disease. J Neurol 246 (1999) 1127-1133
133. Greenacre J.K., Coxon A., Petrie A., et al. Comparison of levodopa with carbidopa or benserazide in parkinsonism. Lancet 2 (1976) 381-384
134. Gschwandtner U., Aston J., Renaud S., et al. Pathologic gambling in patients with Parkinson's disease. Clin Neuropharmacol 24 (2001) 170-172
135. Guldberg H.C., and Marsden C.A. Catechol-O-methyl transferase: pharmacological aspects and physiological role. Pharmacol Rev 27 (1975) 135-206
136. ® dispensible: pharmacokinetics and bioavailability in healthy volunteers. J Neurol 242 Suppl 2 (1995) S140
137. Hakamaki T., Rajala T., and Lehtonen A. Ambulatory 24-hour blood pressure recordings in patients with Parkinson's disease with or without fludrocortisone. Int J Clin Pharmacol Ther 36 (1998) 367-369
138. Han S.K., Mytilineou C., and Cohen G. L-DOPA up-regulates glutathione and protects mesencephalic cultures against oxidative stress. J Neurochem 66 (1996) 501-510
139. Hardie R.J., Malcolm S.L., Lees A.J., et al. The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson's disease who exhibit on-off fluctuations. Br J Clin Pharmacol 22 (1986) 429-436
140. Hardoff R., Sula M., Tamir A., et al. Gastric emptying time and gastric motility in patients with Parkinson's disease. Mov Disord 16 (2001) 1041-1047
141. Hauser R.A., Molho E., Shale H., et al. A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients. Tolcapone De Novo Study Group. Mov Disord 13 (1998) 643-647
142. Heikkinen H., Saraheimo M., Antila S., et al. Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope technique. Eur J Clin Pharmacol 56 (2001) 821-826
143. Hely M.A., Morris J.G., Reid W.G., et al. The Sydney multicentre study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry 57 (1994) 903-910
144. Henry C., and Wilson J.A. Catechol-O-methyltransferase inhibitors in Parkinson's disease. Lancet 351 (1998) 1965-1966
145. Hernan M.A., Zhang S.M., Rueda-deCastro A.M., et al. Cigarette smoking and the incidence of Parkinson's disease in two prospective studies. Ann Neurol 50 (2001) 780-786
146. Hoehn M., and Yahr M. Parkinsonism: onset, progression and mortality. Neurology 17 (1967) 427-442
147. Hoehn M.M. Levodopa-induced postural hypotension. Treatment with fludrocortisone. Arch Neurol 32 (1975) 50-51
148. Hollander E., and Evers M. New developments in impulsivity. Lancet 358 (2001) 949-950
149. Holroyd S., Currie L., and Wooten G.F. Prospective study of hallucinations and delusions in Parkinson's disease. J Neurol Neurosurg Psychiatry 70 (2001) 734-738
150. Horne M.K., Cheng C.H., and Wooten G.F. The cerebral metabolism of L-dihydroxyphenylalanine. An autoradiographic and biochemical study. Pharmacology 28 (1984) 12-26
151. Hornykiewicz O. The mechanisms of action of L-dopa in Parkinson's disease. Life Sci 15 (1974) 1249-1259
152. Hornykiewicz O. L-DOPA: from a biologically inactive amino acid to a successful therapeutic agent. Amino Acids 23 (2002) 65-70
153. Howse P.M., and Matthews W.B. Brocresine in Parkinson's disease. Action of a peripheral and central decarboxylase inhibitor in potentiating levodopa. J Neurol Neurosurg Psychiatry 36 (1973) 27-29
154. Huang Y.C., Colaizzi J.L., Bierman R.H., et al. Pharmacokinetics and dose proportionality of domperidone in healthy volunteers. J Clin Pharmacol 26 (1986) 628-632
155. Hutton J.T., and Morris J.L. Long-term evaluation of Sinemet CR in parkinsonian patients with motor fluctuations. Can J Neurol Sci 18 (1991) 467-471
156. Hutton J.T., Morris J.L., Bush D.F., et al. Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease. Neurology 39 (1989) 67-72 discussion 72-63
157. Inzelberg R., Kipervasser S., and Korczyn A.D. Auditory hallucinations in Parkinson's disease. J Neurol Neurosurg Psychiatry 64 (1998) 533-535
158. Iwase H., Sudo J., Terui J., et al. Transdermal absorption of L-dopa from a new system composed of two separate layers of L-dopa and hydrogel in rats. Drug Dev Ind Pharm 26 (2000) 755-759
159. Jankovic J., Schwartz K., and Vander Linden C. Comparison of Sinemet CR4 and standard Sinemet: double blind and long-term open trial in parkinsonian patients with fluctuations. Mov Disord 4 (1989) 303-309
160. Jankovic J., Gilden J.L., Hiner B.C., et al. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med 95 (1993) 38-48
161. Jellinger K.A. Prevalence of stroke in Parkinson's disease. Mov Disord 18 (2003) 723-724
162. Jenner P. Pharmacology of dopamine agonists in the treatment of Parkinson's disease. Neurology 58 (2002) S1-S8
163. Jenner P. The MPTP-treated primate as a model of motor complications in PD: primate model of motor complications. Neurology 61 (2003) S4-S11
164. Jensen N.O., Dupont E., Hansen E., et al. Madopar HBS: slow-release levodopa and benserazide in parkinsonian patients presenting marked fluctuations in symptoms on standard L-dopa treatment. Eur Neurol 27 Suppl 1 (1987) 68-72
165. Jolkkonen J., Jenner P., and Marsden C.D. L-DOPA reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP. Brain Res Mol Brain Res 32 (1995) 297-307
166. Jorga K., Fotteler B., Schmitt M., et al. The effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/benserazide formulations. Eur Neurol 38 (1997) 59-67
167. Jorga K., Fotteler B., Sedek G., et al. The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation. J Neurol 245 (1998) 223-230
168. Jorga K.M. Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of early studies in volunteers. Neurology 50 (1998) S31-S38
169. Jorga K.M. COMT inhibitors: pharmacokinetic and pharmacodynamic comparisons. Clin Neuropharmacol 21 Suppl 1 (1998) 9-16
170. Jorga K.M., Fotteler B., Heizmann P., et al. Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy. Eur J Clin Pharmacol 54 (1998) 443-447
171. Jorga K.M., Kroodsma J.M., Fotteler B., et al. Effect of liver impairment on the pharmacokinetics of tolcapone and its metabolites. Clin Pharmacol Ther 63 (1998) 646-654
172. Jorga K.M., Larsen J.P., Beiske A., et al. The effect of tolcapone on the pharmacokinetics of benserazide. Eur J Neurol 6 (1999) 211-219
173. Juncos J.L., Mouradian M.M., Fabbrini G., et al. Levodopa methyl ester treatment of Parkinson's disease. Neurology 37 (1987) 1242-1245
174. Kaakkola S. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs 59 (2000) 1233-1250
175. Kaakkola S., and Wurtman R.J. Effects of catechol-O-methyltransferase inhibitors and L-3,4-dihydroxyphenylalanine with or without carbidopa on extracellular dopamine in rat striatum. J Neurochem 60 (1993) 137-144
176. Kafka M.P. The monoamine hypothesis for the pathophysiology of paraphilic disorders: an update. Ann N Y Acad Sci 989 (2003) 86-94 discussion 144-153
177. Kahn N., Freeman A., Juncos J.L., et al. Clozapine is beneficial for psychosis in Parkinson's disease. Neurology 41 (1991) 1699-1700
178. Kalir H.H., and Mytilineou C. Ascorbic acid in mesencephalic cultures: effects on dopaminergic neuron development. J Neurochem 57 (1991) 458-464
179. Kaneoke Y., Koike Y., Sakurai N., et al. Gastrointestinal dysfunction in Parkinson's disease detected by electrogastroenterography. J Auton Nerv Syst 50 (1995) 275-281
180. Kao H.D., Traboulsi A., Itoh S., et al. Enhancement of the systemic and CNS specific delivery of L-dopa by the nasal administration of its water soluble prodrugs. Pharm Res 17 (2000) 978-984
181. Kaufmann H., Nahm K., Purohit D., et al. Autonomic failure as the initial presentation of Parkinson disease and dementia with Lewy bodies. Neurology 63 (2004) 1093-1095
182. Keranen T., Gordin A., Harjola V.P., et al. The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol 16 (1993) 145-156
183. Keranen T., Gordin A., Karlsson M., et al. Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone. Eur J Clin Pharmacol 46 (1994) 151-157
184. Kincannon J., and Boutzale C. The physiology of pigmented nevi. Pediatrics 104 (1999) 1042-1045
185. Kleedorfer B., and Poewe W. Comparative efficacy of two oral sustained-release preparations of L-dopa in fluctuating Parkinson's disease. Preliminary findings in 20 patients. J Neural Transm Park Dis Dement Sect 4 (1992) 173-178
186. Klein C., Kompf D., Pulkowski U., et al. A study of visual hallucinations in patients with Parkinson's disease. J Neurol 244 (1997) 371-377
187. Koller W.C., Hutton J.T., Tolosa E., et al. Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology 53 (1999) 1012-1019
188. Korten A., Lodder J., Vreeling F., et al. Stroke and idiopathic Parkinson's disease: does a shortage of dopamine offer protection against stroke?. Mov Disord 16 (2001) 119-123
189. Kostic V., Przedborski S., Flaster E., et al. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology 41 (1991) 202-205
190. Kostic V.S., Marinkovic J., Svetel M., et al. The effect of stage of Parkinson's disease at the onset of levodopa therapy on development of motor complications. Eur J Neurol 9 (2002) 9-14
191. Kuhn W., Roebroek R., Blom H., et al. Elevated plasma levels of homocysteine in Parkinson's disease. Eur Neurol 40 (1998) 225-227
192. Kurlan R. Disabling repetitive behaviors in Parkinson's disease. Mov Disord 19 (2004) 433-437
193. Kurth M.C. Using liquid levodopa in the treatment of Parkinson's disease. A practical guide. Drugs Aging 10 (1997) 332-340
194. Kurth M.C., Tetrud J.W., Irwin I., et al. Oral levodopa/carbidopa solution versus tablets in Parkinson's patients with severe fluctuations: a pilot study. Neurology 43 (1993) 1036-1039
195. Kurth M.C., Adler C.H., Hilaire M.S., et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I. Neurology 48 (1997) 81-87
196. Lamberti P., Zoccolella S., Iliceto G., et al. Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients. Mov Disord 20 (2005) 69-72
197. Lamberty Y., and Klitgaard H. Consequences of pentylenetetrazole kindling on spatial memory and emotional responding in the rat. Epilepsy Behav 1 (2000) 256-261
198. Lang A.E. Acute orthostatic hypotension when starting dopamine agonist therapy in parkinson disease: the role of domperidone therapy. Arch Neurol 58 (2001) 835
199. Langdon N., Malcolm P.N., and Parkes J.D. Comparison of levodopa with carbidopa, and levodopa with domperidone in Parkinson's disease. Clin Neuropharmacol 9 (1986) 440-447
200. Langer S.Z. Presynaptic regulation of the release of catecholamines. Pharmacol Rev 32 (1980) 337-362
201. Larsen J.P., Worm-Petersen J., Siden A., et al. The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease. Eur J Neurol 10 (2003) 137-146
202. Lautala P., Ethell B.T., Taskinen J., et al. The specificity of glucuronidation of entacapone and tolcapone by recombinant human UDP-glucuronosyltransferases. Drug Metab Dispos 28 (2000) 1385-1389
203. Lawrence de Koning A.B., Werstuck G.H., Zhou J., et al. Hyperhomocysteinemia and its role in the development of atherosclerosis. Clin Biochem 36 (2003) 431-441
204. Leenders K.L., Palmer A.J., Quinn N., et al. Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry 49 (1986) 853-860
205. Lees A.J. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom. BMJ 311 (1995) 1602-1607
206. Lesser R.P., Fahn S., Snider S.R., et al. Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology 29 (1979) 1253-1260
207. LeWitt P.A., Nelson M.V., Berchou R.C., et al. Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies. Neurology 39 (1989) 45-53 discussion 59
208. Li S.T., Dendi R., Holmes C., et al. Progressive loss of cardiac sympathetic innervation in Parkinson's disease. Ann Neurol 52 (2002) 220-223
209. Lieberman A., Gopinathan G., Miller E., et al. Randomized double-blind cross-over study of Sinemet-controlled release (CR4 50/200) versus Sinemet 25/100 in Parkinson's disease. Eur Neurol 30 (1990) 75-78
210. Lieberman A.N., Goldstein M., Gopinathan G., et al. Combined use of benserazide and carbidopa in Parkinson's disease. Neurology 34 (1984) 227-229
211. Lipton S.A., Kim W.K., Choi Y.B., et al. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc Natl Acad Sci USA 94 (1997) 5923-5928
212. Lloyd K.G., Davidson L., and Hornykiewicz O. The neurochemistry of Parkinson's disease: effect of L-dopa therapy. J Pharmacol Exp Ther 195 (1975) 453-464
213. Lotta T., Vidgren J., Tilgmann C., et al. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 34 (1995) 4202-4210
214. Low P.A., Gilden J.L., Freeman R., et al. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group. JAMA 277 (1997) 1046-1051
215. Lozano A.M., Lang A.E., Levy R., et al. Neuronal recordings in Parkinson's disease patients with dyskinesias induced by apomorphine. Ann Neurol 47 (2000) S141-S146
216. Luchsinger J.A., Tang M.X., Shea S., et al. Plasma homocysteine levels and risk of Alzheimer disease. Neurology 62 (2004) 1972-1976
217. Lyons K.E., Hubble J.P., Troster A.I., et al. Gender differences in Parkinson's disease. Clin Neuropharmacol 21 (1998) 118-121
218. Malcolm S.L., Allen J.G., Bird H., et al. Single-dose pharmacokinetics of Madopar HBS in patients and effect of food and antacid on the absorption of Madopar HBS in volunteers. Eur Neurol 27 Suppl 1 (1987) 28-35
219. Mannisto P.T., and Kaakkola S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 51 (1999) 593-628
220. Mannisto P.T., Tuomainen P., Toivonen M., et al. Effect of acute levodopa on brain catecholamines after selective MAO and COMT inhibition in male rats. J Neural Transm Park Dis Dement Sect 2 (1990) 31-43
221. Mannisto P.T., Ulmanen I., Lundstrom K., et al. Characteristics of catechol O-methyl-transferase (COMT) and properties of selective COMT inhibitors. Prog Drug Res 39 (1992) 291-350
222. Maratos E.C., Jackson M.J., Pearce R.K., et al. Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naive MPTP-lesioned common marmosets (Callithrix jacchus). Mov Disord 16 (2001) 631-641
223. Marconi R., Lefebvre-Caparros D., Bonnet A.M., et al. Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology. Mov Disord 9 (1994) 2-12
224. Mark M.H., and Sage J.I. Long-term efficacy of controlled-release carbidopa/levodopa in patients with advanced Parkinson's disease. Ann Clin Lab Sci 19 (1989) 415-421
225. Mark M.H., and Sage J.I. Controlled-release carbidopa-levodopa (Sinemet) in combination with standard Sinemet in advanced Parkinson's disease. Ann Clin Lab Sci 19 (1989) 101-106
226. Markham C., Diamond S.G., and Treciokas L.J. Carbidopa in Parkinson disease and in nausea and vomiting of levodopa. Arch Neurol 31 (1974) 128-133
227. Markianos M., Hadjikonstantinou M., and Bistolaki E. Urinary noradrenaline and serotonin metabolites in drug-free Parkinson patients and the effect of L-dopa treatment. Acta Neurol Scand 66 (1982) 267-275
228. Marsden C.D., and Parkes J.D. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1 (1977) 345-349
229. Marsden C.D., Parkes J.P., and Qinn N. Fluctuations of disability in Parkinson's disease. In: Marsden C.D., and Fahn S. (Eds). Movement Disorders (1982), Butterworth, London
230. Mastaglia F.L., Johnsen R.D., and Kakulas B.A. Prevalence of stroke in Parkinson's disease: a postmortem study. Mov Disord 17 (2002) 772-774
231. Meco G., Pratesi L., and Bonifati V. Cardiovascular reflexes and autonomic dysfunction in Parkinson's disease. J Neurol 238 (1991) 195-199
232. Melamed E., Hefti F., and Wurtman R.J. Nonaminergic striatal neurons convert exogenous L-dopa to dopamine in parkinsonism. Ann Neurol 8 (1980) 558-563
233. Melis M.R., and Argiolas A. Dopamine and sexual behavior. Neurosci Biobehav Rev 19 (1995) 19-38
234. Meltzer H.Y. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21 (1999) 106S-115S
235. Mena M.A., Pardo B., Casarejos M.J., et al. Neurotoxicity of levodopa on catecholamine-rich neurons. Mov Disord 7 (1992) 23-31
236. Mena M.A., Pardo B., Paino C.L., et al. Levodopa toxicity in foetal rat midbrain neurones in culture: modulation by ascorbic acid. Neuroreport 4 (1993) 438-440
237. Mena M.A., Davila V., and Sulzer D. Neurotrophic effects of L-DOPA in postnatal midbrain dopamine neuron/cortical astrocyte cocultures. J Neurochem 69 (1997) 1398-1408
238. Mena M.A., Casarejos M.J., Carazo A., et al. Glia protect fetal midbrain dopamine neurons in culture from L-DOPA toxicity through multiple mechanisms. J Neural Transm 104 (1997) 317-328
239. Menza M.A., Sage J., Marshall E., et al. Mood changes and "on-off" phenomena in Parkinson's disease. Mov Disord 5 (1990) 148-151
240. Menza M.A., Golbe L.I., Cody R.A., et al. Dopamine-related personality traits in Parkinson's disease. Neurology 43 (1993) 505-508
241. Merello M., and Lees A.J. Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson's disease. J Neurol Neurosurg Psychiatry 55 (1992) 1024-1026
242. Merello M., Pirtosek Z., Bishop S., et al. Cardiovascular reflexes in Parkinson's disease: effect of domperidone and apomorphine. Clin Auton Res 2 (1992) 215-219
243. Merims D., Shabtai H., Korczyn A.D., et al. Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson's disease. J Neural Transm 111 (2004) 1447-1453
244. Metman L.V., Hoff J., Mouradian M.M., et al. Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa. Mov Disord 9 (1994) 463-465
245. Michel P.P., and Hefti F. Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J Neurosci Res 26 (1990) 428-435
246. Miller J.W. Homocysteine, folate deficiency, and Parkinson's disease. Nutr Rev 60 (2002) 410-413
247. Miller J.W., Selhub J., Nadeau M.R., et al. Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology 60 (2003) 1125-1129
248. Molina J.A., Sainz-Artiga M.J., Fraile A., et al. Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment?. Mov Disord 15 (2000) 869-872
249. Montastruc J.L., Rascol O., Senard J.M., et al. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. J Neurol Neurosurg Psychiatry 57 (1994) 1034-1038
250. Montastruc J.L., Schmitt L., and Bagheri H. [Pathological gambling behavior in a patient with Parkinson's disease treated with levodopa and bromocriptine.]. Rev Neurol (Paris) 159 (2003) 441-443
251. Moore H., Todd C.L., and Grace A.A. Striatal extracellular dopamine levels in rats with haloperidol-induced depolarization block of substantia nigra dopamine neurons. J Neurosci 18 (1998) 5068-5077
252. Morgante L., Epifanio A., Spina E., et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol 27 (2004) 153-156
253. Morris M.S. Homocysteine and Alzheimer's disease. Lancet Neurol 2 (2003) 425-428
254. Moskovitz C., Moses III H., and Klawans H.L. Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry 135 (1978) 669-675
255. Muenter M.D., and Tyce G.M. L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects. Mayo Clin Proc 46 (1971) 231-239
256. Muller T., Werne B., Fowler B., et al. Nigral endothelial dysfunction, homocysteine, and Parkinson's disease. Lancet 354 (1999) 126-127
257. Muller T., Woitalla D., Hauptmann B., et al. Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease. Neurosci Lett 308 (2001) 54-56
258. Murer M.G., Dziewczapolski G., Menalled L.B., et al. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol 43 (1998) 561-575
259. Myllyla V.V., Sotaniemi K.A., Illi A., et al. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. Eur J Clin Pharmacol 45 (1993) 419-423
260. Myllyla V.V., Jackson M., and Larsen J.P. Efficacy and safety of tolcapone in levodopa-treated Parkinson's disease patients with 'wearing-off' phenomenon: a multicentre, double blind, randomized placebo-controlled trial. Eur J Neurol 4 (1997) 333-341
261. Myllyla V.V., Kultalahti E.R., Haapaniemi H., et al. FILOMEN Study Group. Twelve-month safety of entacapone in patients with Parkinson's disease. Eur J Neurol 8 (2001) 53-60
262. Mytilineou C., Han S.K., and Cohen G. Toxic and protective effects of L-dopa on mesencephalic cell cultures. J Neurochem 61 (1993) 1470-1478
263. Naber D., and Lambert M. Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism. Prog Neuropsychopharmacol Biol Psychiatry 28 (2004) 1213-1219
264. Nakaso K., Yasui K., Kowa H., et al. Hypertrophy of IMC of carotid artery in Parkinson's disease is associated with L-DOPA, homocysteine, and MTHFR genotype. J Neurol Sci 207 (2003) 19-23
265. Napolitano A., Zurcher G., and Da Prada M. Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats. Eur J Pharmacol 273 (1995) 215-221
266. Nausieda P.A., Tanner C.M., and Klawans H.L. Serotonergically active agents in levodopa-induced psychiatric toxicity reactions. Adv Neurol 37 (1983) 23-32
267. Nausieda P.A., Pfeiffer R.F., Tagliati M., et al. A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease. Clin Ther 27 (2005) 58-63
268. Nilsson D., Hansson L.E., Johansson K., et al. Long-term intraduodenal infusion of a water based levodopa-carbidopa dispersion in very advanced Parkinson's disease. Acta Neurol Scand 97 (1998) 175-183
269. Nilsson D., Nyholm D., and Aquilonius S.M. Duodenal levodopa infusion in Parkinson's disease-long-term experience. Acta Neurol Scand 104 (2001) 343-348
270. Nissinen E., Kaheinen P., Penttila K.E., et al. Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson's disease, does not impair mitochondrial energy production. Eur J Pharmacol 340 (1997) 287-294
271. Nissinen E., Nissinen H., Larjonmaa H., et al. The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats. J Neural Transm 112 9 (2005) 1213-1221
272. Noble E.P. The DRD2 gene in psychiatric and neurological disorders and its phenotypes. Pharmacogenomics 1 (2000) 309-333
273. Nordera G.P., Lorizio A., Lion P., et al. Treatment of parkinsonian conditions with a controlled-release form of levodopa-preliminary study. Eur Neurol 27 Suppl 1 (1987) 76-80
274. Novartis Pharmaceuticals Corporation. COMTAN Prescribing Information (2000), East Hanover, New Jersey, USA
275. Novartis Pharmaceuticals Corporation. CLOZARIL Prescribing Information (2005), East Hanover, New Jersey
276. Nutt J.G. On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics. Ann Neurol 22 (1987) 535-540
277. Nutt J.G. Levodopa-induced dyskinesia: review, observations, and speculations. Neurology 40 (1990) 340-345
278. Nutt J.G. Pharmacokinetics and pharmacodynamics of levodopa. In: Koller W.C. (Ed). Handbook of Parkinson's Disease (1992), Marcel Dekker, New York 411-732
279. Nutt J.G. Catechol-O-methyltransferase inhibitors for treatment of Parkinson's disease. Lancet 351 (1998) 1221-1222
280. Nutt J.G. Effect of COMT inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 55 (2000) S33-S37 discussion S38-S41
281. Nutt J.G., and Fellman J.H. Pharmacokinetics of levodopa. Clin Neuropharmacol 7 (1984) 35-49
282. Nutt J.G., Woodward W.R., and Anderson J.L. The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism. Ann Neurol 18 (1985) 537-543
283. Nutt J.G., Gancher S.T., and Woodward W.R. Does an inhibitory action of levodopa contribute to motor fluctuations?. Neurology 38 (1988) 1553-1557
284. Nutt J.G., Woodward W.R., Beckner R.M., et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 44 (1994) 913-919
285. Nutt J.G., Carter J.H., and Woodward W.R. Long-duration response to levodopa. Neurology 45 (1995) 1613-1616
286. Nyholm D., Askmark H., Gomes-Trolin C., et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol 26 (2003) 156-163
287. Nyholm D., Nilsson Remahl A.I., Dizdar N., et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 64 (2005) 216-223
288. Obeso J.A., and Olanow C.W. Dopamine agonists in early Parkinson's disease. In: Olanow C.W., and Obeso J.A. (Eds). Beyond the Decade of the Brain Vol. 2. (1997), Wells Medical Ltd, Tunbridge Wells, Kent, UK 11-35
289. Obeso J.A., Rodriguez-Oroz M.C., Chana P., et al. The evolution and origin of motor complications in Parkinson's disease. Neurology 55 (2000) S13-S20 discussion S21-S13
290. Olanow C.W. Tolcapone and hepatotoxic effects. Tasmar Advisory Panel. Arch Neurol 57 (2000) 263-267
291. Olanow C.W., Hauser R.A., Gauger L., et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 38 (1995) 771-777
292. Olanow C.W., Watts R.L., and Koller W.C. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 56 (2001) S1-S88
293. Ondo W.G., Levy J.K., Vuong K.D., et al. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord 17 (2002) 1031-1035
294. Ondo W.G., Tintner R., Dat Voung K., et al. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord 20 8 (2005) 958-963
295. Onofrj M., Thomas A., Iacono D., et al. Switch-over from tolcapone to entacapone in severe Parkinson's disease patients. Eur Neurol 46 (2001) 11-16
296. O'Suilleabhain P.E., Bottiglieri T., Dewey Jr. R.B., et al. Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease. Mov Disord 19 (2004) 1403-1408
297. O'Suilleabhain P.E., Sung V., Hernandez C., et al. Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. Arch Neurol 61 (2004) 865-868
298. Pacchetti C., Martignoni E., Sibilla L., et al. Effectiveness of Madopar HBS plus Madopar standard in patients with fluctuating Parkinson's disease: two years of follow-up. Eur Neurol 30 (1990) 319-323
299. Pahwa R., Busenbark K., Huber S.J., et al. Clinical experience with controlled-release carbidopa/levodopa in Parkinson's disease. Neurology 43 (1993) 677-681
300. Papa S.M., Desimone R., Fiorani M., et al. Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias. Ann Neurol 46 (1999) 732-738
301. Papavasiliou P.S., Cotzias G.C., Duby S.E., et al. Levodopa in Parkinsonism: potentiation of central effects with a peripheral inhibitor. N Engl J Med 286 (1972) 8-14
302. Papavasiliou P.S., Cotzias G.C., and Lawrence W.H. Levodopa and dopamine in cerebrospinal fluid. Neurology 23 (1973) 756-759
303. Pappert E.J., Goetz C.G., Niederman F., et al. Liquid levodopa/carbidopa produces significant improvement in motor function without dyskinesia exacerbation. Neurology 47 (1996) 1493-1495
304. Pappert E.J., Goetz C.G., Niederman F.G., et al. Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease. Mov Disord 14 (1999) 117-121
305. Pardo B., Mena M.A., Fahn S., et al. Ascorbic acid protects against levodopa-induced neurotoxicity on a catecholamine-rich human neuroblastoma cell line. Mov Disord 8 (1993) 278-284
306. Parker Jr. W.D., Boyson S.J., and Parks J.K. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 26 (1989) 719-723
307. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. N Engl J Med 321 (1989) 1364-1371
308. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol 39 (1996) 37-45
309. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Ann Neurol 39 (1996) 29-36
310. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 42 (1997) 747-755
311. Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. The Parkinson Study Group. N Engl J Med 340 (1999) 757-763
312. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 284 (2000) 1931-1938
313. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287 (2002) 1653-1661
314. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 59 (2002) 1937-1943
315. Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med 351 (2004) 2498-2508
316. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 61 (2004) 1044-1053
317. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 61 (2004) 561-566
318. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62 (2005) 241-248
319. Pearce R.K., Banerji T., Jenner P., et al. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov Disord 13 (1998) 234-241
320. Perry E.K., Kerwin J., Perry R.H., et al. Visual hallucinations and the cholinergic system in dementia. J Neurol Neurosurg Psychiatry 53 (1990) 88
321. Perry I.J., Refsum H., Morris R.W., et al. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 346 (1995) 1395-1398
322. Perry T.L., Godin D.V., and Hansen S. Parkinson's disease: a disorder due to nigral glutathione deficiency?. Neurosci Lett 33 (1982) 305-310
323. Pezzoli G., Tesei S., Ferrante C., et al. Madopar HBS in fluctuating parkinsonian patients: two-year treatment. Mov Disord 3 (1988) 37-45
324. Pfeiffer R.F. Gastrointestinal dysfunction in Parkinson's disease. Clin Neurosci 5 (1998) 136-146
325. Pfeiffer R.F. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol 2 (2003) 107-116
326. Physicians Desk Reference (2003), Thomson PDR, Montvale, NJ
327. Piccini P., Brooks D.J., Korpela K., et al. The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. J Neurol Neurosurg Psychiatry 68 (2000) 589-594
328. Poewe W.H., Lees A.J., and Stern G.M. Low-dose L-dopa therapy in Parkinson's disease: a 6-year follow-up study. Neurology 36 (1986) 1528-1530
329. Poewe W.H., Lees A.J., and Stern G.M. Clinical and pharmacokinetic observations with Madopar HBS in hospitalized patients with Parkinson's disease and motor fluctuations. Eur Neurol 27 Suppl 1 (1987) 93-97
330. Poewe W.H., Deuschl G., Gordin A., et al. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand 105 (2002) 245-255
331. Poewe W.H., Deuschl G., Gordin A., et al. CELOMEN Study Group. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand 105 (2002) 245-255
332. Postuma R.B., and Lang A.E. Homocysteine and levodopa: should Parkinson disease patients receive preventative therapy?. Neurology 63 (2004) 886-891
333. Quigley E.M. Gastrointestinal dysfunction in Parkinson's disease. Semin Neurol 16 (1996) 245-250
334. Quinn N., Marsden C.D., and Parkes J.D. Complicated response fluctuations in Parkinson's disease: response to intravenous infusion of levodopa. Lancet 2 (1982) 412-415
335. Quinn N.P., Toone B., Lang A.E., et al. Dopa dose-dependent sexual deviation. Br J Psychiatry 142 (1983) 296-298
336. Quinn N.P., Marion M.H., and Marsden C.D. Open study of Madopar HBS, a new formulation of levodopa with benserazide, in 13 patients with Parkinson's disease and 'on-off' fluctuations. Eur Neurol 27 Suppl 1 (1987) 105-113
337. Rabey J.M., Vardi J., Askenazi J.J., et al. L-tryptophan administration in L-dopa-induced hallucinations in elderly Parkinsonian patients. Gerontology 23 (1977) 438-444
338. Rabey J.M., Treves T.A., Neufeld M.Y., et al. Low-dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson's disease. Neurology 45 (1995) 432-434
339. Rabey J.M., Sagi I., Huberman M., et al. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol 23 (2000) 324-330
340. Rajput A.H., Stern W., and Laverty W.H. Chronic low-dose levodopa therapy in Parkinson's disease: an argument for delaying levodopa therapy. Neurology 34 (1984) 991-996
341. Rajput A.H., Martin W., Saint-Hilaire M.H., et al. Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology 49 (1997) 1066-1071
342. Rascol O., Brooks D.J., Korczyn A.D., et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342 (2000) 1484-1491
343. Rascol O., Brooks D.J., Melamed E., et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365 (2005) 947-954
344. Reinikainen K., Leinonen M., and Isojarvi J. Predicting the need for levodopa dose reduction after entacapone initiation in PD patients with end-of-dose wearing-off. Mov Disord 17 Suppl 5 (2002) P111
345. Riederer P., Youdim M.B., Rausch W.D., et al. On the mode of action of L-deprenyl in the human central nervous system. J Neural Transm 43 (1978) 217-226
346. Riederer P., Sofic E., Rausch W.D., et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52 (1989) 515-520
347. Rinne U.K., and Molsa P. Levodopa with benserazide or carbidopa in Parkinson disease. Neurology 29 (1979) 1584-1589
348. Rinne U.K., Larsen J.P., Siden A., et al. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 51 (1998) 1309-1314
349. Rinne U.K., Bracco F., Chouza C., et al. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 55 Suppl 1 (1998) 23-30
350. Roberts J.W., Cora-Locatelli G., Bravi D., et al. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology 43 (1993) 2685-2688
351. Rodnitzky R.L., Dickins Q.S., and Dobson J. Long-term clinical efficacy of Sinemet CR in patients with Parkinson's disease. Neurology 39 (1989) 92-95 discussion 95
352. Rogers J.D., Sanchez-Saffon A., Frol A.B., et al. Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. Arch Neurol 60 (2003) 59-64
353. Rondot P., Ziegler M., Aymard N., et al. Effect of controlled-release carbidopa/levodopa on motor performance in advanced Parkinson's disease. Neurology 39 (1989) 74-77 discussion 95
354. Rouru J., Gordin A., Huupponen R., et al. Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition. Eur J Clin Pharmacol 55 (1999) 461-467
355. 18F]fluorodopa utilization after COMT inhibition with entacapone studied with PET in advanced Parkinson' disease. J Neural Transm Park Dis Dement Sect 10 (1995) 91-106
356. Ruottinen H.M., and Rinne U.K. Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. Clin Neuropharmacol 19 (1996) 222-233
357. Ruottinen H.M., and Rinne U.K. A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease. Clin Neuropharmacol 19 (1996) 283-296
358. Sachs C., Berglund B., and Kaijser L. Autonomic cardiovascular responses in parkinsonism: effect of levodopa with dopa-decarboxylase inhibition. Acta Neurol Scand 71 (1985) 37-42
359. Sage J.I., and Mark M.H. Comparison of controlled-release Sinemet (CR4) and standard Sinemet (25 mg/100 mg) in advanced Parkinson's disease: a double-blind, crossover study. Clin Neuropharmacol 11 (1988) 174-179
360. Sanchez-Ramos J.R., Ortoll R., and Paulson G.W. Visual hallucinations associated with Parkinson disease. Arch Neurol 53 (1996) 1265-1268
361. Sasahara K., Nitanai T., Habara T., et al. Dosage form design for improvement of bioavailability of levodopa II: bioavailability of marketed levodopa preparations in dogs and parkinsonian patients. J Pharm Sci 69 (1980) 261-265
362. 18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease. Neurology 44 (1994) 1292-1297
363. Schapira A.H., Cooper J.M., Dexter D., et al. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 54 (1990) 823-827
364. Schonfeldt-Lecuona C., and Connemann B.J. Aripiprazole and Parkinson's disease psychosis. Am J Psychiatry 161 (2004) 373-374
365. Schrag A., and Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 123 Pt 11 (2000) 2297-2305
366. Schultz E., and Nissinen E. Inhibition of rat liver and duodenum soluble catechol-O-methyltransferase by a tight-binding inhibitor OR-462. Biochem Pharmacol 38 (1989) 3953-3956
367. Schultz E., Nissinen E., and Kaakkola S. Determination of catechol-O-methyltransferase activity in erythrocytes by high performance liquid chromatography with electrochemical detection. Biomed Chromatogr 3 (1989) 64-67
368. Schultz W. Responses of midbrain dopamine neurons to behavioral trigger stimuli in the monkey. J Neurophysiol 56 (1986) 1439-1461
369. Sedek G., Jorga K., Schmitt M., et al. Effect of tolcapone on plasma levodopa concentrations after coadministration with levodopa/carbidopa to healthy volunteers. Clin Neuropharmacol 20 (1997) 531-541
370. Seedat S., Kesler S., Niehaus D.J., et al. Pathological gambling behaviour: emergence secondary to treatment of Parkinson's disease with dopaminergic agents. Depress Anxiety 11 (2000) 185-186
371. Senard J.M., Verwaerde P., Rascol O., et al. Effects of acute levodopa administration on blood pressure and heart variability in never treated parkinsonians. Hypertens Res 18 Suppl 1 (1995) S175-S177
372. Senard J.M., Rai S., Lapeyre-Mestre M., et al. Prevalence of orthostatic hypotension in Parkinson's disease. J Neurol Neurosurg Psychiatry 63 (1997) 584-589
373. Seshadri S., Beiser A., Selhub J., et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 346 (2002) 476-483
374. Shaffer H., and Hall M. Estimating the prevalence of adolescent gambling disorders: a quantitative synthesis and guide toward standard gambling nomenclature. J Gambl Stud 12 (1996) 193-214
375. Sharf B., Moskovitz C., Lupton M.D., et al. Dream phenomena induced by chronic levodopa therapy. J Neural Transm 43 (1978) 143-151
376. Shoulson I., Glaubiger G.A., and Chase T.N. On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 25 (1975) 1144-1148
377. Siegfried J. Therapeutic value of Madopar HBS: judgment after 2 years experience. Eur Neurol 27 Suppl 1 (1987) 98-104
378. Siemers E.R., Shekhar A., Quaid K., et al. Anxiety and motor performance in Parkinson's disease. Mov Disord 8 (1993) 501-506
379. Sigurdardottir G.R., Nilsson C., Odin P., et al. Cardiovascular effects of domperidone in patients with Parkinson's disease treated with apomorphine. Acta Neurol Scand 104 (2001) 92-96
380. Skibba J.L., Pinckley J., Gilbert E.F., et al. Multiple primary melanoma following administration of levodopa. Arch Pathol 93 (1972) 556-561
381. Smith L.A., Gordin A., Jenner P., et al. Entacapone enhances levodopa-induced reversal of motor disability in MPTP-treated common marmosets. Mov Disord 12 (1997) 935-945
382. Smith L.A., Tel B.C., Jackson M.J., et al. Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation. Mov Disord 17 (2002) 887-901
383. Smith L.A., Jackson M.J., Hansard M.J., et al. Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naive MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure. Mov Disord 18 (2003) 487-495
384. Smith L.A., Jackson M.J., Al-Barghouthy G., et al. Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates. Mov Disord 20 (2005) 306-314
385. Sofic E., Paulus W., Jellinger K., et al. Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem 56 (1991) 978-982
386. Squires R.F. Multiple forms of monoamine oxidase in intact mitochondria as characterized by selective inhibitors and thermal stability: a comparison of eight mammalian species. Adv Biochem Psychopharmacol 5 (1972) 355-370
387. Steckler T., and Sahgal A. The role of serotonergic-cholinergic interactions in the mediation of cognitive behaviour. Behav Brain Res 67 (1995) 165-199
388. Steece-Collier K., Collier T.J., Sladek C.D., et al. Chronic levodopa impairs morphological development of grafted embryonic dopamine neurons. Exp Neurol 110 (1990) 201-208
389. Steiger M.J., Stocchi F., Bramante L., et al. The clinical efficacy of single morning doses of levodopa methyl ester: dispersible Madopar and Sinemet plus in Parkinson disease. Clin Neuropharmacol 15 (1992) 501-504
390. Stern M., Dulaney E., Gruber S.B., et al. The epidemiology of Parkinson's disease. A case-control study of young-onset and old-onset patients. Arch Neurol 48 (1991) 903-907
391. Stocchi F., Barbato L., Bramante L., et al. The clinical efficacy of a single afternoon dose of levodopa methyl ester: a double-blind cross-over study versus placebo. Funct Neurol 9 (1994) 259-264
392. Stocchi F., Barbato L., Bramante L., et al. Fluctuating parkinsonism: a pilot study of single afternoon dose of levodopa methyl ester. J Neurol 243 (1996) 377-380
393. Struck L.K., Rodnitzky R.L., and Dobson J.K. Stroke and its modification in Parkinson's disease. Stroke 21 (1990) 1395-1399
394. Sudo J., Iwase H., Terui J., et al. Transdermal absorption of L-dopa from hydrogel in rats. Eur J Pharm Sci 7 (1998) 67-71
395. Sweet R.D., Lee J.E., and McDowell F.H. Methyldopa as an adjunct to levodopa treatment of Parkinson's disease. Clin Pharmacol Ther 13 (1972) 23-27
396. Syed N., Murphy J., Zimmerman Jr. T., et al. Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease. Mov Disord 13 (1998) 336-338
397. Thompson J.F., Scolyer R.A., and Kefford R.F. Cutaneous melanoma. Lancet 365 (2005) 687-701
398. Tohgi H., Abe T., Takahashi S., et al. Alterations in the concentration of serotonergic and dopaminergic substances in the cerebrospinal fluid of patients with Parkinson's disease, and their changes after L-dopa administration. Neurosci Lett 159 (1993) 135-138
399. Tohgi H., Abe T., Yamazaki K., et al. Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson's disease: correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement. Neurosci Lett 192 (1995) 165-168
400. Tolosa E., Marti M.J., Valldeoriola F., et al. History of levodopa and dopamine agonists in Parkinson's disease treatment. Neurology 50 (1998) S2-S10 discussion S44-S18
401. Tornwall M., Kaakkola S., Tuomainen P., et al. Comparison of two new inhibitors of catechol O-methylation on striatal dopamine metabolism: a microdialysis study in rats. Br J Pharmacol 112 (1994) 13-18
402. Tretter L., Sipos I., and Adam-Vizi V. Initiation of neuronal damage by complex I deficiency and oxidative stress in Parkinson's disease. Neurochem Res 29 (2004) 569-577
403. Troconiz I.F., Naukkarinen T.H., Ruottinen H.M., et al. Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone. Clin Pharmacol Ther 64 (1998) 106-116
404. Trugman J.M., James C.L., and Wooten G.F. D1/D2 dopamine receptor stimulation by L-dopa. A [14C]-2-deoxyglucose autoradiographic study. Brain 114 Pt 3 (1991) 1429-1440
405. U.K. Madopar CR Study Group. A comparison of Madopar CR and standard Madopar in the treatment of nocturnal and early-morning disability in Parkinson's disease. Clin Neuropharmacol 12 (1989) 498-505
406. Uitti R.J., Tanner C.M., Rajput A.H., et al. Hypersexuality with antiparkinsonian therapy. Clin Neuropharmacol 12 (1989) 375-383
407. Valeant Pharmaceuticals International. Prescribing information Tasmar (tolcapone) USA (2006), Valeant Pharmaceuticals International, Aliso Viejo, CA
408. van Deelen R.A., Rommers M.K., Eerenberg J.G., et al. [Hypersexuality during use of levodopa]. Ned Tijdschr Geneeskd 146 (2002) 2095-2098
409. Verhagen Metman L., Locatelli E.R., Bravi D., et al. Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications. Neurology 48 (1997) 369-372
410. Vogel H.P., and Schiffter R. Hypersexuality-a complication of dopaminergic therapy in Parkinson's disease. Pharmacopsychiatria 16 (1983) 107-110
411. von Bohlen und Halbach O., and Dermietzel R. Dopamine. Neurotransmitters and Neuromodulators (2002), Wiley-VCH Verlag GmbH & Co, KGaA, Weinheim
412. Wakabayashi K., and Takahashi H. Neuropathology of autonomic nervous system in Parkinson's disease. Eur Neurol 38 Suppl 2 (1997) 2-7
413. Wakabayashi K., Takahashi H., Ohama E., et al. Lewy bodies in the visceral autonomic nervous system in Parkinson's disease. Adv Neurol 60 (1993) 609-612
414. Waters C.H., Kurth M., Bailey P., et al. Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. The Tolcapone Stable Study Group. Neurology 49 (1997) 665-671
415. Webster R.A. Dopamine (DA). In: Webster R.A. (Ed). Neurotransmitters, Drugs and Brain Function (2001), John Wiley & Sons Ltd, New York
416. Weiner W.J., Singer C., Sanchez-Ramos J.R., et al. Levodopa, melanoma, and Parkinson's disease. Neurology 43 (1993) 674-677
417. Westin J.E., Andersson M., Lundblad M., et al. Persistent changes in striatal gene expression induced by long-term L-DOPA treatment in a rat model of Parkinson's disease. Eur J Neurosci 14 (2001) 1171-1176
418. Whone A.L., Watts R.L., Stoessl A.J., et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 54 (2003) 93-101
419. Wick M.M. Levodopa and dopamine analogs: melanin precursors as antitumor agents in experimental human and murine leukemia. Cancer Treat Rep 63 (1979) 991-997
420. Wick M.M. Levodopa and dopamine analogs as DNA polymerase inhibitors and antitumor agents in human melanoma. Cancer Res 40 (1980) 1414-1418
421. Wick M.M. Inhibition of transformation by levodopa-carbidopa in lymphocytes derived from patients with melanoma. J Invest Dermatol 88 (1987) 535-537
422. Wick M.M. Levodopa/dopamine analogs as inhibitors of DNA synthesis in human melanoma cells. J Invest Dermatol 92 (1989) 329S-331S
423. Wikberg T., Ottoila P., and Taskinen J. Identification of major urinary metabolites of the catechol-O-methyltransferase inhibitor entacapone in the dog. Eur J Drug Metab Pharmacokinet 18 (1993) 359-367
424. Wikberg T., Vuorela A., Ottoila P., et al. Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans. Drug Metab Dispos 21 (1993) 81-92
425. Wilde M.I., and Markham A. Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications. Drugs 52 (1996) 773-794
426. Wilding I.R., Hardy J.G., Davis S.S., et al. Characterisation of the in vivo behaviour of a controlled-release formulation of levodopa (Sinemet CR). Clin Neuropharmacol 14 (1991) 305-321
427. Wolters E.C., and Tesselaar H.J. International (NL-UK) double-blind study of Sinemet CR and standard Sinemet (25/100) in 170 patients with fluctuating Parkinson's disease. J Neurol 243 (1996) 235-240
428. Wolters E.C., Horstink M.W., Roos R.A., et al. Clinical efficacy of Sinemet CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's disease. An open, and a double-blind, double-dummy, multicenter treatment evaluation. The Dutch Sinemet CR Study Group. Clin Neurol Neurosurg 94 (1992) 205-211
429. Wright C.B., Lee H.S., Paik M.C., et al. Total homocysteine and cognition in a tri-ethnic cohort: the Northern Manhattan Study. Neurology 63 (2004) 254-260
430. Yahr M.D., Duvoisin R.C., Mendoza M.R., et al. Modification of L-dopa therapy of Parkinsonism by alpha-methyldopa hydrazine (MK-486). Trans Am Neurol Assoc 96 (1971) 55-58
431. Yamamoto M., Yokochi M., Kuno S., et al. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease. J Neural Transm 104 (1997) 229-236
432. Yasui K., Kowa H., Nakaso K., et al. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology 55 (2000) 437-440
433. Yasui K., Nakaso K., Kowa H., et al. Levodopa-induced hyperhomocysteinaemia in Parkinson's disease. Acta Neurol Scand 108 (2003) 66-67
434. Yeh K.C., August T.F., Bush D.F., et al. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. Neurology 39 (1989) 25-38
435. Zeng B.Y., Pearce R.K., MacKenzie G.M., et al. Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA. Eur J Neurosci 12 (2000) 1096-1104
436. Ziv I., Zilkha-Falb R., Offen D., et al. Levodopa induces apoptosis in cultured neuronal cells-a possible accelerator of nigrostriatal degeneration in Parkinson's disease?. Mov Disord 12 (1997) 17-23
437. Zoldan J., Friedberg G., Livneh M., et al. Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology 45 (1995) 1305-1308
438. Zurcher G., Colzi A., and Da Prada M. Ro 40-7592: inhibition of COMT in rat brain and extracerebral tissues. J Neural Transm Suppl 32 (1990) 375-380